Abstract
INTRODUCTION
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide [1] [2] [3] . The number of deaths per year from HCC is nearly identical to the worldwide incidence, highlighting the incredibly high case fatality rate of this aggressive disease [3] . While the highest prevalence of HCC is among populations in Asia and Africa, the incidence of HCC has been increasing in the United States, due to the growing number of patients with nonalcoholic steatohepatitis (NASH) and chronic hepatitis C virus (HCV) who are at risk for HCC [1, [4] [5] [6] [7] [8] . However, the rising HCC incidence is not uniform across all groups, and an increasingly disproportionate rise in HCC incidence among minority groups, and in particular Hispanics, have been reported [9] [10] [11] [12] [13] . A recent study by White et al [7] reported a 4.5% annual increase in overall HCC incidence in the United States from 2000 to 2009. However, race/ethnicityspecific differences were observed with significantly greater increases in HCC incidence among Hispanics, such that beginning in 2012, HCC incidence among Hispanics surpassed that of Asians in the United States. While the exact etiology underlying this epidemiology is unclear, these trends likely reflect the successful impact of HBV vaccination in Asians and the emergence of nonalcoholic fatty liver disease (NAFLD) in the Hispanic population. Because the Hispanic population carries a disproportionate burden of NAFLD, understanding trends in HCC among the Hispanic population in the United States may provide insight on NAFLD-HCC trends [11, [14] [15] [16] [17] [18] [19] . The aim of the current study is to evaluate overall trends and disparities in HCC outcomes among Hispanic HCC patients in the United States with a focus on HCC tumor stage at presentation.
MATERIALS AND METHODS
The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) population based cancer registry was reviewed to identify all Hispanic adults (age 20 years and older) with HCC from 2004 to 2014 in the United States [20] . The 2004-2014 SEER data includes data from 18 regions in the United States (San Francisco-Oakland, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San JoseMonterey, Los Angeles, Alaska Natives, Rural Georgia, California excluding San Francisco/San Jose/Los Angeles, Kentucky, Louisiana, New Jersey, and Greater Georgia) and represents approximately 28% of the United States population.
The International Classification of Disease for Oncology, Third Edition was used by the SEER database to define HCC [21] . HCC tumor stage was evaluated using SEER historic summary staging, which is unique to SEER and is not used particularly for prognosis, but to describe the extent of disease [21] . Tumors confined to only one lobe of the liver with or without vascular invasion were defined as localized. Tumors involving more than one lobe through contiguous growth of a single lesion, extension to adjacent structures (gallbladder, diaphragm, or extrahepatic bile ducts), or spread to regional lymph nodes were defined as regional. Metastatic disease or extension of cancer to distant lymph nodes or nearby organs such as the stomach, pleura, or pancreas was defined as distant. In addition to SEER HCC staging, we also evaluated tumor characteristics including size and number of tumors to determine whether a patient's tumor met Milan criteria (single lesion less than 5 cm or no more than 3 lesions each less than 3 cm) with no extrahepatic or vascular involvement. We specifically chose to evaluate whether or not a patient's tumor met Milan criteria, as this affects eligibility for liver transplantation, which is one of the major curative treatment options for HCC [22] . Insurance status was evaluated using SEER classifications, which included three categories: Medicare or commercial insurance, Medicaid, and uninsured/no insurance. Medicare or commercial insurance includes patients with private insurance (fee-for-service, managed care, HMO, PPO, Tricare) or Medicare (administered through a managed care plan, Medicare with private supplement, or Medicare with supplement, NOS and Military). Medicaid includes patients with Medicaid (including administered through managed care plans, Medicare with Medicaid eligibility, and Indian/Public Health Service). Uninsured is defined as those who were either not insured or self-pay at time of HCC diagnosis. Age-specific comparisons utilized three categories of age at time of HCC diagnosis (age < 50 years, age 50 -64 years, and age > 65 years).
Statistical analysis
Demographic characteristics of the study cohort were presented as proportions and frequencies. Overall proportion of adult Hispanic patients with localized HCC or HCC within Milan criteria were stratified by sex, age at time of diagnosis, insurance status, and year of diagnosis, and compared across groups using χ2 test. Predictors of HCC tumor stage at presentation and HCC treatment received were evaluated using multivariate logistic regression models. Forward stepwise regression methods were used with variables demonstrating significant associations in the univariate model (P < 0.10) or those with biologic significance determined a priori (e.g., age and sex) included in the final model. Statistical significance was met with a 2-tailed P-value < 0.05. All statistical analyses were performed with Stata version 14 (Stata Corp, College Station, TX). The study was reviewed and determined to be exempt by the Alameda Health System Institutional Review Board because human subjects were not involved, as per United States Department of Health and Human Services guidelines, and the SEER database is publicly available without individually identifiable private information.
RESULTS
Hispanics accounted for 19.8% of all HCC among United States adults in the 2004-2014 SEER registry, with the majority of subjects with HCC being men (n = 9856, 73.3%). Among both Hispanic men and women with HCC, 60.9% had Medicare or commercial insurance at time of HCC diagnosis, 33.5% had Medicaid, and 5.6% were uninsured ( Table 1 ). The proportion of the HCC cohort represented by Hispanic patients increased from 17.6% in 2004-2006 to 20.1% in 2013-2014. When evaluating HCC tumor stage at diagnosis, 38.0% of Hispanic HCC patients were within Milan criteria, and 54.0% of Hispanic HCC patients had localized HCC (Table 2 ). Compared to female HCC patients, male HCC patients had significantly lower rates of localized HCC (52.8% vs 57.6%, P < 0.001) and significantly lower rates of HCC within Milan criteria (37.4% vs 39.7%, P = 0.01). Compared to HCC patients age < 50 years at time of diagnosis, higher rates of localized HCC and HCC within Milan criteria were observed in those age 50-64, but HCC patients age > 65 years had lower rates of localized HCC or HCC within Milan criteria (Table 2 ). Compared to Medicare or commercially insured patients, Hispanic HCC patients with Medicaid or no insurance had significantly lower rates of localized HCC or HCC within Milan criteria.
When stratified by year of HCC diagnosis, Hispanic HCC patients in the latter time periods had significantly higher rates of localized HCC at time of diagnosis, and in 2013-2014, 56.9% of Hispanic HCC patients had localized tumor stage. Similarly, the proportion of Hispanic patients with HCC within Milan criteria also increased with time, and in 2013-2014, 42.6% of Hispanic HCC patients were within Milan criteria (Table 3) . When stratified by sex, age, and insurance status, similar trends were seen, such that HCC patients in latter time periods had the highest rates of more localized stage of disease. On multivariate regression, in comparison to Medicare/commercially insured Hispanic HCC patients, uninsured patients were significantly less likely to have HCC within Milan criteria at time of diagnosis (OR 0.49, 95%CI: 0.40-0.59, P < 0.001), whereas no significant difference was observed in Medicaid HCC patients (Figure 1 
DISCUSSION
Using United States population-based cancer registry data, the current study evaluated disparities in HCC tumor stage at diagnosis with a focus on Hispanics with HCC. Overall, the proportion of HCC in the Hispanic population increased during the study period such that over 20% of HCC patients in the United States during 2013-2014 were of Hispanic ethnicity. Despite this huge disease burden among the Hispanic population, less than half of Hispanic HCC patients were within Milan criteria at the time of diagnosis in the most recent time period studied. Furthermore, significant disparities among this group were observed, with a disproportionately higher risk of advanced tumor stage at presentation among Hispanic men, older Hispanic patients, and uninsured Hispanic patients. Nearly one in five HCC patients in the United States are of Hispanic ethnicity with Hispanic patients showing the greatest increase in the incidence of HCC from 2004-2006 to 2013-2014 [20] . These observations are consistent with previous SEER registry based studies evaluating trends in HCC incidence. For example, El-Serag et al [23] reported significantly greater age-adjusted HCC incidence rates in Hispanic patients in comparison to non-Hispanic white and black populations between 1992 and 2002. This increasing HCC incidence among the Hispanic population in the United States has continued to rise such that HCC incidence among Hispanics surpassed HCC incidence among Asians in 2012 to become the ethnic group with the greatest incidence of HCC in the United States and representing over 20% of all HCC among adults in the United States [7] . While our current study is limited by the ability to evaluate the liver disease etiology contributing to HCC, the Hispanic population in the United States carries a disproportionate burden of NAFLD [14] [15] [16] [17] [24] [25] [26] [27] [28] . Furthermore, during this same period where Hispanics have become the ethnic group with the most rapidly rising incidence of HCC, it is also important to note that prevalence of NASHrelated HCC has also risen in parallel [8, 18, 26, [29] [30] [31] . Two recent studies using the SEERMedicare database and the United Network for Organ Sharing registry demonstrate the continued rising prevalence of NAFLD-related HCC in the United States [8, 18] . While the growing burden of HCC among the Hispanic population is concerning, it is even more alarming that the Hispanic population faces significant disparities in access to treatment options for HCC, which contributes to significantly lower survival [32] [33] [34] [35] . A recent study by Ha et al [34] using the SEER database found that Hispanic patients with HCC had significantly lower rates of curative HCC treatment when compared to non-Hispanic whites. Hispanics were also significantly less likely to receive liver transplantation even after correcting for stage of disease at time of diagnosis. Our current analysis of the most recent SEER database continues to highlight these disparities among the Hispanic HCC population. Despite improvements in earlier tumor stage of diagnosis over time, even in the most recent 2013-2014 period only 42.6% of Hispanic HCC patients were within Milan criteria at the time of diagnosis, which means that nearly 60% of patients were not eligible for liver transplantation, one of the main curative options for HCC patients. A greater frequency of HCC was observed among male patients within our study, which is consistent with prior data showing HCC rates in males are two to four times as high as rates in females [35, 36] . This sex-specific trend in HCC risk is also observed among NAFLD HCC populations. Corey et al [36] evaluated at risk factors for HCC in 94 patients with NAFLD with HCC and 150 patients with NAFLD without HCC. The strongest association with risk of HCC was being male, with males having a four-fold higher risk of developing HCC compared to females. The majority of Hispanic HCC patients in our study were men, and they had more advanced HCC at diagnosis compared to females. Similarly Yang et al [37] observed significantly better outcomes in females with HCC. In their study of primarily non-Hispanic Caucasian patients, the distribution of tumor burden showed a higher incidence of single lesions among women and a higher incidence of vascular invasion among men.
Our study utilized a large population-based cancer registry, which represents a large proportion of the United States population. The SEER registry allowed for a large sample size and comprehensive analysis of HCC epidemiology and outcomes. Despite this, the current study has several limitations that should be acknowledged. SEER does not include etiology of HCC (e.g., chronic hepatitis B virus, chronic HCV, alcoholic liver disease, or NAFLD), which may have affected rates of disease progression or rates of timely HCC screening and surveillance. Along the same lines, liver disease-specific treatment data (e.g., antiviral therapies) were not available for inclusion in the analysis. While our study observed more advanced tumor stage among older patients, this observation may be confounded by other factors. Older patients may have had more significant co-morbidities (hypertension, diabetes mellitus, or cardiac disease) that may have affected referral for HCC screening and surveillance. However, these additional co-morbidities and risk factors such as alcohol use, obesity, and concurrent diabetes mellitus were not available in the database for inclusion in our analyses. While our study also investigated disparities related to insurance status, we acknowledge that insurance status is only one key factor that is tightly linked to other demographic and socioeconomic factors in a complex manner. Furthermore, in the SEER database, Medicare and commercially insured patients are combined into one category, and demographic and clinical differences between those with Medicare and commercial insurance may affect HCC stage at diagnosis. However, access to care, including HCC screening and surveillance that would affect tumor stage and HCC treatment are expected to be similar between those with Medicare and commercial insurance in the United States. While our study found significant disparities in HCC stage among uninsured patients, these differences may reflect difficulty accessing healthcare due to complex socioeconomic needs. However, these data were not available to assess further in the database. Another factor not readily available for analysis is concurrent substance use and highrisk behavior, which may have affected timely access and adherence to HCC surveillance. Lastly, surveillance data were not available to evaluate how the differences in successful screening and surveillance rates contributed to the observed disparities in HCC stage at diagnosis. Despite these limitations, our study provides valuable information regarding a vulnerable subset of the United States population.
Understanding HCC trends provides valuable data to guide clinicians and policy makers to identify high-risk groups as well as those that suffer disparities towards which resources can be targeted to improve HCC screening and surveillance for early detection and treatment. Our current study focused specifically on Hispanic HCC patients, a group that has the highest incidence of HCC in the United States since 2012 and represents 20% of all adults with HCC. Among this group less than 40% had HCC within Milan criteria at the time of diagnosis, and thus over 60% were ineligible for liver transplantation, one of the major curative options for HCC patients. Part of this problem revolves around effective HCC screening and surveillance, and despite established guidelines, overall HCC screening rates remain low [38] [39] [40] . In one United States population-based study, less than 20% of patients with cirrhosis who developed HCC received regular surveillance, and only 29% of patients who had a diagnosis of HCC had undergone annual surveillance in the three years before receiving the diagnosis [41] . Tavakoli et al [42] observed that less than half of cirrhotic patients received first time HCC screening among safety-net populations with cirrhosis, with the largest disparity occurring among patients with NASH cirrhosis. Improved efforts at HCC screening and surveillance are needed, particularly among Hispanic patients, a growing population with a high prevalence of NAFLD. 
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Research background
Hepatocellular carcinoma (HCC) is a leading cause of morbidity and mortality worldwide. The Hispanic population represents a major contributor of HCC prevalence, particularly in the United States. Understanding HCC epidemiology and disparities in HCC outcomes among this cohort will help guide interventions to improve HCC care.
Research motivation
Given the significant burden of HCC among the Hispanic population, understanding HCC epidemiology and outcomes among this group is critical. Data gathered from studying HCC epidemiology can help identify potential areas where quality improvement programs can be developed and implemented to improve management of HCC.
Research objectives
The main objective of this study was to evaluate disparities in cancer stage at diagnosis among Hispanic HCC patients.
Research methods
The current study utilized a large United States national-based cancer registry. We utilized a retrospective observational cohort study design to evaluate HCC epidemiology and outcomes among Hispanic adults diagnosed with HCC from 2004 to 2014.
Research results
We identified that over 60% of Hispanic HCC patients were diagnosed with advanced cancer stage that was beyond eligibility for liver transplantation. This highlights an important disparity and may reflect suboptimal utilization of timely HCC screening and surveillance among this population.
Research conclusions
These findings may suggest that the Hispanic population at risk for HCC may experience suboptimal receipt of or delays in timely HCC screening and surveillance. These study findings further add to the existing literature highlighting the poor adherence to HCC screening and surveillance among at-risk populations. Specifically, our study identified a high-risk group in the Hispanic population, which is particularly concerning given the higher risk of nonalcoholic fatty liver disease in this population, a disease that is increasing in prevalence.
Research perspectives
Our study findings emphasize the importance of timely and consistent implementation of HCC screening and surveillance that will translate into improved early HCC detection. This will ultimately improve treatment options for curative intent and thus improve long-term survival outcomes among HCC patients.
